F-star Therapeutics CEO Eliot Forster's 2020 pay jumps 193% to $4.5M
F-star Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 7, 2021
F-star Therapeutics reported fiscal year 2020 executive compensation information on April 7, 2021.
In 2020, eight executives at F-star Therapeutics received on average a compensation package of $1.5M, a 46% increase compared to previous year.
Average pay of disclosed executives at F-star Therapeutics
Eliot Forster, Chief Executive Officer, received $4.5M in total, which increased by 193% compared to 2019. 77% of Forster's compensation, or $3.5M, was in option awards. Forster also received $402K in bonus, $645K in salary, as well as $1.9K in other compensation.
Neil Brewis, Chief Scientific Officer, received a compensation package of $1.7M, which increased by 234% compared to previous year. 64% of the compensation package, or $1.1M, was in option awards.
Neil Brewis, PhD., DSc, Chief Scientific Officer, earned $1.7M in 2020.
Louis Kayitalire, Chief Medical Officer, received $1M in 2020, which increases by 39% compared to 2019.
Darlene Deptula-Hicks, Chief Financial Officer, earned $983K in 2020, a 13% increase compared to previous year.
R.P. Kris Iyer, Chief Scientific Officer, received $842K in 2020, which decreases by 5% compared to 2019.
Martin Driscoll, Chief Executive Officer, earned $688K in 2020, a 52% decrease compared to previous year.
Jonathan Freve, Chief Financial Officer, received $230K in 2020, which decreases by 77% compared to 2019.
Related executives
Eliot Forster
F-star Therapeutics
Chief Executive Officer
Darlene Deptula-Hicks
F-star Therapeutics
Chief Financial Officer
Louis Kayitalire
F-star Therapeutics
Chief Medical Officer
Neil Brewis
F-star Therapeutics
Chief Scientific Officer
RP Iyer
F-star Therapeutics
Chief Scientific Officer
Martin Driscoll
F-star Therapeutics
Chief Executive Officer
Jonathan Freve
F-star Therapeutics
Chief Financial Officer
Neil DSc
F-star Therapeutics
Chief Scientific Officer
You may also like
Source: SEC filing on April 7, 2021.